NICE issues recommendations for Imbruvica

In September, the U.K.'s NICE issued final appraisal determination recommending Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) within the Cancer Drugs Fund (CDF) to treat Waldenstrom’s macroglobulinemia in patients treated with at least one prior therapy or as first-line in patients ineligible for chemo-immunotherapy -- its approved indication. The list price for Imbruvica is £4,599 ($6,183) for a 30-day supply. The company will offer the drug under a patient access scheme.

The agency also issued draft guidance recommending against the use of Imbruvica to treat relapsed or refractory mantle cell lymphoma. NICE said it would consider a CDF proposal for Imbruvica in the indication...